Key facts
- Merck is discussing potential use of its COVID antiviral molnupiravir for Ebola.
- CEPI is providing over $60 million for Ebola Bundibugyo vaccine development.
- Moderna will receive up to $50 million from CEPI for vaccine development.
- No approved vaccines or treatments exist for the rare Ebola Bundibugyo strain.
- The DRC outbreak has resulted in 282 confirmed cases and 42 deaths.
The Ebola Bundibugyo strain outbreak in the Democratic Republic of Congo presents a significant public health challenge, particularly as there are no approved vaccines or treatments specifically for this strain. The potential repurposing of existing antiviral drugs like Merck's molnupiravir highlights the urgent need for therapeutic options to combat the spread and severity of the disease. Efforts are underway to develop specific vaccines, with CEPI accelerating development.